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A B S T R A C T
Aﬀective disorders including depression and anxiety are among the most prevalent behavioral abnormalities in
patients with Alzheimer's disease (AD), which aﬀect the quality of life and progression of the disease.
Dysregulation of the hypothalamic-pituitary-adrenal-(HPA) axis has been reported in aﬀective disorders and AD.
Recent studies revealed that current antidepressant drugs are not completely eﬀective for treating anxiety- and
depression-related disorders in people with dementia. ATP-sensitive-potassium-(KATP) channels are well-known
to be involved in AD pathophysiology, HPA axis function and the pathogenesis of depression and anxiety-related
behaviors. Thus, targeting of KATP channel may be a potential therapeutic strategy in AD. Hence, we investigated
the eﬀects of intracerebroventricular injection of Aβ25-35 alone or in combination with glibenclamide, KATP
channel inhibitor on depression- and anxiety-related behaviors as well as HPA axis response to stress in rats. To
do this, non-Aβ25-35- and Aβ25-35-treated rats were orally treated with glibenclamide, then the behavioral
consequences were assessed using sucrose preference, forced swim, light-dark box and plus maze tests. Stress-
induced corticosterone levels following forced swim and plus maze tests were also evaluated as indicative of
abnormal HPA-axis-function. Aβ25-35 induced HPA axis hyperreactivity and increased depression- and anxiety-
related symptoms in rats. Our results showed that blockade of KATP channels with glibenclamide decreased
depression- and anxiety-related behaviors by normalizing HPA axis activity in Aβ25-35-treated rats. This study
provides additional evidence that Aβ administration can induce depression- and anxiety-like symptoms in ro-
dents, and suggests that KATP channel inhibitors may be a plausible therapeutic strategy for treating aﬀective
disorders in AD patients.
1. Introduction
Alzheimer disease (AD) is one of the most common neurodegen-
erative diseases aﬀecting millions of individuals in developing societies,
but the exact pathological cause remained unknown (Kalaria et al.,
2008; Wood and Cummings, 2004). To date, the amyloid hypothesis has
been considered as the most prevalent theory to explain the patho-
physiology of AD. According to this hypothesis, one of the neuro-
pathology characteristics of AD is an accumulation of senile and neu-
roﬁbrillary tangles, mainly composed of β-amyloid (Aβ) peptide and
highly phosphorylated tau proteins in the brain (Accardi et al., 2012;
Hardy and Selkoe, 2002; Karran et al., 2011). These structures accu-
mulate progressively in diﬀerent brain regions, leading to memory
impairment and neuronal damage (Babri et al., 2014; Fjell et al., 2014).
In the last decade, chronic stress and adverse lifestyle have been
shown to be serious risk factors for development and progression of AD
in humans (Marcello et al., 2015; Pardon, 2011; Zvěřová et al., 2013).
Stress was found to contribute signiﬁcantly in accelerating AD-related
phenotypes and cognitive decline (Sotiropoulos et al., 2011). In addi-
tion, experimental stressful conditions were shown to aggravate Aβ-
pathology in animal models of AD (Baglietto-Vargas et al., 2015; Green
et al., 2006; Jeong et al., 2006). The most important stress system
which is physiologically activated in response to actual or presumed
environmental challenges is hypothalamic pituitary adrenal (HPA) axis
(Noschang et al., 2012). Activation of this neuroendocrine stress system
triggers the release of glucocorticoid hormones including cortisol in
humans and corticosterone in rodents from the adrenal cortex (Brureau
et al., 2013). These steroid hormones can easily cross blood-brain
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